PCSK9 and familial hypercholesterolemia: Another therapeutic acting as a Pcsk9 inhibitor, human monoclonal antibody—alirocumab, was approved by the FDA in 2015 for the treatment of heterozygous familial hypercholesterolemia and atherosclerosis.